BioMarin Announces Record Revenues in First Quarter 2022
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
BioMarin Pharma (BMRN) Tops Q1 EPS by 46c
April 27, 2022 4:16 PM EDTBioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of $0.63, $0.46 better than the analyst estimate of $0.17. Revenue for the quarter came in at $519 million versus the consensus estimate of $507.52 million.
GUIDANCE:
BioMarin Pharma sees FY2022 revenue of $2.05-2.15 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
... More